Medicine and Dentistry
Abatacept
50%
Adverse Event
5%
Anti-Citrullinated Protein Antibody
16%
Arthralgia
11%
Awareness
12%
Blood Clotting
9%
Circulating Tumor DNA
8%
Clinical Stage
5%
Colorectal Adenoma
50%
Colorectal Carcinoma
12%
Colorectal Polyp
12%
Disease Resistance
8%
Diseases
26%
DNA Determination
8%
Drug Therapy
11%
Epidermal Growth Factor Receptor
50%
Epidermal Growth Factor Receptor Kinase Inhibitor
50%
Fibrinogen
50%
Hazard Ratio
11%
Inflammatory Arthritis
27%
Intention-to-Treat Analysis
11%
Liquid Biopsy
8%
Lymphocyte
50%
Magnetic Resonance Imaging
33%
Medicine
5%
Monotherapy
50%
Multivariate Analysis
17%
Neoplasm
12%
Next Generation Sequencing
8%
Non Small Cell Lung Cancer
100%
Non-Small Cell Lung Cancer
50%
Osimertinib
25%
Osteitis
5%
Overall Survival
50%
Placebo
50%
Platelet
50%
Polypectomy
12%
Resistance Mutation
50%
Rheumatoid Arthritis
27%
Senescence
12%
Serositis
9%
Surgery
50%
Synovitis
5%
Tenosynovitis
5%
Univariate Analysis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Abatacept
50%
Adverse Event
5%
Arthralgia
11%
Circulating Tumor DNA
8%
Cyclic Citrullinated Peptide Antibody
16%
Disease
13%
Disease Resistance
8%
Epidermal Growth Factor Receptor
50%
Epidermal Growth Factor Receptor Kinase Inhibitor
50%
Inflammation
27%
Inflammatory Arthritis
27%
Molecular Target
8%
Monotherapy
50%
Neoplasm
8%
Non Small Cell Lung Cancer
50%
Osimertinib
25%
Osteitis
5%
Placebo
50%
Rheumatoid Arthritis
27%
Synovitis
5%
Tenosynovitis
5%
